-
Product Insights
NewChikungunya Fever – Drugs In Development, 2024
Empower your strategies with our Chikungunya Fever – Drugs In Development, 2024 report and make more profitable business decisions. Chikungunya is a viral disease transmitted to humans by the bite of infected Aedes aegypti mosquitoes. Chikungunya virus (CHIKV) is a member of the genus Alpha virus, in the family Togaviridae. Symptoms of Chikungunya includes debilitating arthralgia (joint pain), swelling of joints, stiffness of joints, myalgia (muscular pain), headache, fatigue (weakness), nausea, vomiting, and rash and fever. Treatment includes use of non-steroidal...
-
Product Insights
NewAllergic Asthma – Drugs In Development, 2024
Empower your strategies with our Allergic Asthma – Drugs In Development, 2024 report and make more profitable business decisions. Allergic asthma is a type of asthma triggered by exposure to allergens, substances that induce an allergic reaction in susceptible individuals. When someone with allergic asthma encounters these triggers, their immune system responds by inflaming and constricting the airways, leading to symptoms of asthma. Common allergens that can trigger asthma include pollen, dust mites, pet dander, mold, cockroach droppings, and certain foods....
-
Product Insights
NewAllergic Rhinitis – Drugs In Development, 2024
Empower your strategies with our Allergic Rhinitis – Drugs In Development, 2024 report and make more profitable business decisions. Allergic rhinitis is an allergic reaction that happens when immune system overreacts to substances that is inhaled. An allergen is something that triggers an allergy. When a person with allergic rhinitis breathes in an allergen such as pollen, mold, animal dander, or dust, the body releases chemicals that cause allergy symptoms. Symptoms of allergic rhinitis include stuffy or runny nose, sneezing, swollen...
-
Sector Analysis
Gout Market Opportunity Assessment, Epidemiology, Clinical Trials, Unmet Needs and Forecast to 2032
Gout Market Report Overview The Gout market across the 7MM (7MM: the US, France, Germany, Italy, Spain, the UK, and Japan) was valued at $4.63 billion in 2022. Significant growth is expected at a CAGR of more than 8% from 2022 to 2032 as the gout population steadily increases and novel therapies enter the market. Furthermore, the US had the highest number of diagnosed prevalent cases of gout across the 7MM, in 2022, followed by Japan and France. Diagnosed prevalent cases...
-
Product Insights
Cardiac Ablation Devices Pipeline by Development Stages, Segments, Region and Countries, Regulatory Path and Key Companies
Cardiac Ablation Devices Pipeline Market Report Overview Cardiac ablation devices use radiofrequency energy to destroy cardiac tissues which propagate incorrect electrical signals to cause an abnormal heart rhythm. The cardiac ablation devices pipeline market research report provides a comprehensive understanding of the pipeline products along with their comparative analysis at various stages of development. The report also includes information about the territories wherein the clinical trials are in progress, the regulatory paths followed by the trials, and the companies associated...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – PRT-3645 in Laryngeal Cancer
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. PRT-3645 in Laryngeal Cancer Drug Details: PRT-3645 is under development for the treatment of solid...
-
Sector Analysis
Insomnia Market Opportunity Assessment, Epidemiology, Clinical Trials, Unmet Needs and Forecast to 2032
Insomnia Market Report Overview The Insomnia market across the 7MM (7MM: the US, France, Germany, Italy, Spain, the UK, and Japan) was valued at $3.2 billion in 2022. Steady growth is anticipated at a CAGR of more than 2% from 2022 to 2032, due to the launch of four novel pipeline agents - Hetlioz, SM-1, vornorexant, and sunobinop. The insomnia market research report offers an overview of insomnia, including its epidemiology, symptoms, diagnosis, and disease management. The report offers key...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Dabrafenib Mesylate in Refractory Multiple Myeloma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Dabrafenib Mesylate in Refractory Multiple Myeloma report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Dabrafenib Mesylate in Refractory Multiple Myeloma Drug Details: Dabrafenib...